INH14
Based on 5 publication(s) in Google Scholar
INH14 is a cell permeable inhibitor of IKKα/IKKβ, with IC50s of 8.97 and 3.59 μM, respectively. INH14 inhibits the IKKα/β-dependent TLR inflammatory response. INH14 also inhibits downstream of TAK1/TAB1 and NF-kB pathways. Anti-inflammatory and anti-cancer activity.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 98.0%
- CAS. Nr.: 200134-22-1
- Formel: C15H16N2O
- Molecular Weight:240.30
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
HY-B0713
AmlexanoxIKK Inhibitor -
HY-13453
BAY 11-7082IκBα/NF-κB Inhibitor -
HY-15473
MLN120BIKKβ Inhibitor -
HY-111941
GSK8612TBK1 Inhibitor -
HY-W067427
BAY32-5915IKKα Inhibitor -
HY-10519
BMS-345541IKK-1/IKK-2 Inhibitor -
HY-10172
IMD-0354IKKβ Inhibitor -
HY-10518
BMS-345541 hydrochlorideIKK-1/IKK-2 Inhibitor -
HY-13802
SC-514IKK Inhibitor -
HY-13060
ACHP HydrochlorideIKKβ Inhibitor -
HY-12453
TBK1/IKKε-IN-2TBK1/IKKε Inhibitor -
HY-128679
TBK1/IKKε-IN-5TBK1/IKKε Inhibitor
Publications Citing Use of MedChemExpress (MCE) INH14
More
Biologische Aktivität
Beschreibung
IC50 & Target
[1]|
IKKβ 3.59 μM (IC50) |
IKKα 8.97 μM (IC50) |
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:8-week old, male, pathogen-free C57BL/6J mice[1]
-
Dosage:5 µg/g, one hour before Pam2CSK4 injection
-
Administration:I.P. for 2 hours
-
Result:Decreased TNFα production in mice.
Chemical Information
-
CAS. Nr. 200134-22-1
-
Appearance Solid
-
Molecular Weight 240.30
-
Formel C15H16N2O
-
Color White to off-white
-
SMILES
O=C(NC1=CC=CC=C1)NC2=CC=C(CC)C=C2
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (5)
-
Journal Impact Factor
-
Most Recent
-
J Ethnopharmacol
Mechanism of Qingjie Fuzheng Granules in inhibiting colitis associated colorectal cancer by regulating TLR4 and IL-4R mediated macrophage polarization. [Abstract]2025 Mar 26:344:119511. PMID: 39978444 -
Exp Cell Res
The involvement of endogenous melatonin in LPS-induced M1-like macrophages and its underlying synthesis mechanism regulated by IRF3. [Abstract]2024 Nov 1;443(1):114314. PMID: 39481795 -
Adipocyte
MAPKs/AP-1, not NF-κB, is responsible for MCP-1 production in TNF-α-activated adipocytes. [Abstract]2022 Dec;11(1):477-486. PMID: 35941819 -
Biol Pharm Bull
Astragaloside IV Regulates the PI3K/Akt/HO-1 Signaling Pathway and Inhibits H9c2 Cardiomyocyte Injury Induced by Hypoxia-Reoxygenation. [Abstract]2019 May 1;42(5):721-727. PMID: 30867343 -
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : ≥ 125 mg/mL (520.18 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (8.66 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protokoll
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Reinheit & Dokumentation
-
Data Sheet (272 KB)
-
SDS (701 KB)
- English - EN (701 KB)
- Français - FR (701 KB)
- Deutsch - DE (701 KB)
- Norwegian - NO (701 KB)
- Español - ES (701 KB)
- Swedish - SV (701 KB)
- Italian - IT (701 KB)
- Korean - KR (701 KB)
- Portuguese - PT (701 KB)
-
Handling Instructions (2659 KB)
Verweise
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.1615 mL | 20.8073 mL | 41.6146 mL | 104.0366 mL |
| 5 mM | 0.8323 mL | 4.1615 mL | 8.3229 mL | 20.8073 mL | |
| 10 mM | 0.4161 mL | 2.0807 mL | 4.1615 mL | 10.4037 mL | |
| 15 mM | 0.2774 mL | 1.3872 mL | 2.7743 mL | 6.9358 mL | |
| 20 mM | 0.2081 mL | 1.0404 mL | 2.0807 mL | 5.2018 mL | |
| 25 mM | 0.1665 mL | 0.8323 mL | 1.6646 mL | 4.1615 mL | |
| 30 mM | 0.1387 mL | 0.6936 mL | 1.3872 mL | 3.4679 mL | |
| 40 mM | 0.1040 mL | 0.5202 mL | 1.0404 mL | 2.6009 mL | |
| 50 mM | 0.0832 mL | 0.4161 mL | 0.8323 mL | 2.0807 mL | |
| 60 mM | 0.0694 mL | 0.3468 mL | 0.6936 mL | 1.7339 mL | |
| 80 mM | 0.0520 mL | 0.2601 mL | 0.5202 mL | 1.3005 mL | |
| 100 mM | 0.0416 mL | 0.2081 mL | 0.4161 mL | 1.0404 mL |
INH14 Related Classifications
HY-114454 Related Classifications
Powered by Bioz